Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 1.00 |
| ▸ | HSD11B2 | P80365 | 11/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | CES2 | O00748 | 3/20 | 0.65 |
| ▸ | CES1 | P23141 | 3/20 | 0.65 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.65 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.63 |
| ▸ | PRKCH | P24723 | 1/20 | 0.63 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycyrrhizin SCHEMBL15833919 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL7688850 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL17880405 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL21424347 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL24626512 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL11007323 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL23309804 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL13294344 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL23747025 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 | |
| Glycyrrhizin SCHEMBL14514292 | 1.00 | HSD11B1 (1.00) | HSD11B1HSD11B2SLCO1B3SLCO1B1HMGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210876-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PENTACYCLIC TRITERPENOIDS | SPV TIMSER, S.A.P.I. DE C.V. (MX) | 2023-07-06 | — | — | US | disclosed |
| US-20220168230-A1 | NANOPARTICLE MEDIATED THERAPY | YALE UNIVERSITY | 2022-06-02 | — | — | US | disclosed |
| WO-2021074158-A1 | ORAL CARE COMPOSITION | LACER, S.A. (ES) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021074164-A1 | ORAL CARE COMPOSITON | LACER, S.A. (ES) | 2021-04-22 | — | — | WO | disclosed |
| EP-3808327-A1 | ORAL CARE COMPOSITON | Lacer, S.A. (ES) | 2021-04-21 | — | — | EP | disclosed |
| US-20200214989-A1 | NANOMATERIALS WITH ENHANCED DRUG DELIVERY EFFICIENCY | YALE UNIVERSITY | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210876-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PENTACYCLIC TRITERPENOIDS | CYP11B2, CYP4A11, CYP11B1 | HSD11B1 8/4885HSD11B2 13/4885SLCO1B3 1641/4885 |
| US-20200214989-A1 | NANOMATERIALS WITH ENHANCED DRUG DELIVERY EFFICIENCY | VIP, SI, LSS | HSD11B1 298/4885HSD11B2 439/4885SLCO1B3 1079/4885 |
| US-20220168230-A1 | NANOPARTICLE MEDIATED THERAPY | LSS, CYP46A1, CYP51A1 | HSD11B1 36/4885HSD11B2 190/4885SLCO1B3 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.